Bimolecular optical probes
First Claim
1. A composition of matter comprising:
- a) a peptide wherein the peptide is selected from the group consisting of;
ALRRFSLGEK (SEQ ID NO;
47),ALRRFS*LGEK (SEQ ID NO;
97),RGGLFSTTPGGTK (SEQ ID NO;
50),RGGLFS*TTPGGTK (SEQ ID NO;
100),KLNRVFSVAC (SEQ ID NO;
58);
KLNRVFS*VAC (SEQ ID NO;
108),RPRTFSSLAEGK (SEQ ID NO;
63),RPRTFSS*LAEGK (SEQ ID NO;
113),AKHPFSPKKAK (SEQ ID NO;
69),AKHPFS*PKKAK (SEQ ID NO;
119),DDEFTAYVATRK (SEQ ID NO;
75),DDEFT*AYVATRK (SEQ ID NO;
125),TGIFTEYVATRK (SEQ ID NO;
76),TGIFT*EYVATRK (SEQ ID NO;
126),TGVFTQHVATRK (SEQ ID NO;
77),TGVFT*QHVATRK (SEQ ID NO;
127),QRIFSIANSIVK (SEQ ID NO;
80),QRIFS*IANSIVK (SEQ ID NO;
130),RIDSIAFSIVGK (SEQ ID NO;
83),RIDSIAFS*IVGK (SEQ ID NO;
133),EEDAFSIIGK (SEQ ID NO;
90),EEDAFS*IIGK (SEQ ID NO;
140),REDEFSQNEEK (SEQ ID NO;
91),REDEFS*QNEEK (SEQ ID NO;
141),IIKIFSPDVEK (SEQ ID NO;
70),IIKIFS*PDVEK (SEQ ID NO;
120),EGDYSQVLEK (SEQ ID NO;
22), andEGDYS*QVLEK (SEQ ID NO;
144),wherein S* represents a phosphorylated serine and T* represents a phosphorylated threonine;
b) a first detectable moiety; and
c) a second detectable moiety.
6 Assignments
0 Petitions
Accused Products
Abstract
Compositions, methods, and kits for detecting and monitoring post-translational modification activities, including kinase or phosphatase activities, are described. The compositions typically include a peptide, a first detectable moiety, a first binding member, and a protease cleavage site. Modification of a composition by a post-translational modification enzyme, such as a kinase or phosphatase, alters the proteolytic sensitivity of the peptide, resulting in a change of a detectable property of the composition when it is associated noncovalently with a probe composition that includes a second binding member and a second detectable moiety. Panel assays for determining substrates or modulators of enzymatic activities are also described.
-
Citations
24 Claims
-
1. A composition of matter comprising:
-
a) a peptide wherein the peptide is selected from the group consisting of; ALRRFSLGEK (SEQ ID NO;
47),ALRRFS*LGEK (SEQ ID NO;
97),RGGLFSTTPGGTK (SEQ ID NO;
50),RGGLFS*TTPGGTK (SEQ ID NO;
100),KLNRVFSVAC (SEQ ID NO;
58);KLNRVFS*VAC (SEQ ID NO;
108),RPRTFSSLAEGK (SEQ ID NO;
63),RPRTFSS*LAEGK (SEQ ID NO;
113),AKHPFSPKKAK (SEQ ID NO;
69),AKHPFS*PKKAK (SEQ ID NO;
119),DDEFTAYVATRK (SEQ ID NO;
75),DDEFT*AYVATRK (SEQ ID NO;
125),TGIFTEYVATRK (SEQ ID NO;
76),TGIFT*EYVATRK (SEQ ID NO;
126),TGVFTQHVATRK (SEQ ID NO;
77),TGVFT*QHVATRK (SEQ ID NO;
127),QRIFSIANSIVK (SEQ ID NO;
80),QRIFS*IANSIVK (SEQ ID NO;
130),RIDSIAFSIVGK (SEQ ID NO;
83),RIDSIAFS*IVGK (SEQ ID NO;
133),EEDAFSIIGK (SEQ ID NO;
90),EEDAFS*IIGK (SEQ ID NO;
140),REDEFSQNEEK (SEQ ID NO;
91),REDEFS*QNEEK (SEQ ID NO;
141),IIKIFSPDVEK (SEQ ID NO;
70),IIKIFS*PDVEK (SEQ ID NO;
120),EGDYSQVLEK (SEQ ID NO;
22), andEGDYS*QVLEK (SEQ ID NO;
144),wherein S* represents a phosphorylated serine and T* represents a phosphorylated threonine; b) a first detectable moiety; and c) a second detectable moiety. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)
-
Specification